InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD, Inc. announced that the U.S. FDA has approved its Investigational Device Exemption (IDE) application to initiate the pivotal CGUARDIANS III study of its SwitchGuard Neuro Protection System. This next-generation device is designed for use in transcarotid artery revascularization procedures with the CGuard Prime stent to prevent strokes. T…